Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients

NCT00636740 is registered in ClinicalTrials.gov with Merrion Pharmaceuticals, LLC as lead sponsor.

NCT NCT00636740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00636740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients
Lead sponsor
Merrion Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
February 28, 2009
Enrollment
30 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-refractory prostate cancer